Back in January, Valeant Pharmaceuticals' CEO J. Michael Pearson couldn't say how he intended to reach his lofty goal of cracking the list of top 5 drugmakers worldwide. Now, he's offering new details about his acquisition blueprints, and they include deals in ophthalmology, dermatology and dentistry.
Valeant CEO Michael Pearson has never been a fan of drug R&D. Openly caustic in the past about the risk involved in drug research, Valeant's chief executive has largely steered clear of developing a pipeline, focusing instead on a clear strategy involving the rapid acquisition of marketed drugs.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug...
Pfizer celebrated three birthdays January 1. That's when it officially divided its business into three distinct units, each with its own management and financial reporting--and each with its own prospect of setting off on its own, at least eventually. Analysts are betting that one of those three businesses will be first to go: Already, potential buyers are buzzing.
J. Michael Pearson is one ambitious man. The Valeant ($VRX) CEO wants to elbow his way to the top echelons of the drug business. If he has his way, Valeant will be one of the top 5 drugmakers in the world. By 2016.
Valeant Pharmaceuticals has added another $250 million deal to its buyout tally, with a $250 million bid to buy Solta Medical, a maker of dermatological treatment devices. And Endo Health Solutions has agreed to pay up to $220 million for NuPathe and its brand-new migraine treatment Zecuity.
Valeant CEO J. Michael Pearson has turned his company into a force in a buying spree that he most recently topped off with the $8.7 billion deal that snagged Bausch + Lomb. But sometimes you can buy trouble.
With Valeant Pharmaceuticals forking over $8.7 billion for eye-care giant Bausch + Lomb and Amgen's $10.4 billion deal for Onyx Pharmaceuticals, this could be a comeback year for pharma M&A, even as the drug approval rate remains healthy.
According to a new report from consultant PwC, there was a decline in the two Vs--volume and value--after some big deals in the first quarter pushed both of those up.
There's been a lot of talk about a dearth of innovation in the pharma business. But some drugmakers don't lack creativity. In fact, a few of them actually made Forbes' latest list of 100 most innovative companies on the globe.